Pooja Bhagia - Concepedia

Author

Pooja Bhagia

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

Lucjan Wyrwicz, P. Bhagia, Pooja Bhagia, Sergey Afanasyev

107

Publications

7.4K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)National Cancer Center Hospital East Yonsei University KU Leuven Cornell University

About

Pooja Bhagia is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in cancer therapeutics, oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	27	4.3K
2	Pathology	16	25	2.3K
3	Gastroenterology	12	12	1.7K
4	Immunology	11	11	906
5	Health Sciences	10	10	2.3K

Pooja Bhagia

Publications

7.2K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study Jong‐Mu Sun, Lin Shen, Manish A. Shah, The Lancet Chemotherapy Versus ChemotherapyOncologyEsophageal CancerGastrointestinal OncologyClinical Trials	2021	1.5K
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer Takashi Kojima, Manish A. Shah, Kei Muro, Journal of Clinical Oncology	2020	1.1K
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer Yelena Y. Janjigian, Akihito Kawazoe, Patricio Yañez, Nature Gastrointestinal OncologyMedicineHer2 BlockadeImmunologyGastroenterology	2021	648
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Sun Young Rha, Do‐Youn Oh, Patricio Yañez, The Lancet Oncology Chemotherapy Versus PlaceboGastrointestinal OncologyMedicineClinical TrialsImmune Checkpoint Inhibitor	2023	521
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus Manish A. Shah, Takashi Kojima, Daniel Hochhauser, JAMA Oncology	2018	511
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials Joseph Chao, Charles S. Fuchs, Kohei Shitara, JAMA Oncology	2021	415
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial Yelena Y. Janjigian, Akihito Kawazoe, Yuxian Bai, The Lancet Her2-positive GastricGastrointestinal OncologyInterim AnalysesMedicineGastroenterology	2023	390
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study Kohei Shitara, Sun Young Rha, Lucjan Wyrwicz, The Lancet Oncology Interim AnalysisSurgical OncologyOncologyGastrointestinal OncologyGastroenterology	2023	294
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. Takashi Kojima, Kei Muro, Éric François, Journal of Clinical Oncology Advanced Esophageal CancerEsophageal CancerGastrointestinal OncologyMedicineCancer Management	2019	207
Isolation and transcriptome analyses of human erythroid progenitors: BFU-E and CFU-E Jie Li, John Hale, Pooja Bhagia, Blood	2014	181

Page 1